ROCKWELL MEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.455 USD | -3.64% |
|
+0.34% | -23.02% |
| Apr. 17 | Rockwell Medical Continues to Expand Its Distribution Capabilities in Western United States | CI |
| Apr. 04 | Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 156.1 | 94.51 | 38.53 | 11.81 | 53.85 | 42.73 | - |
| Enterprise Value (EV) 1 | 156.1 | 94.51 | 38.53 | 11.81 | 53.85 | 42.73 | 42.73 |
| P/E ratio | -4.36 x | -2.46 x | -1.17 x | -0.54 x | -5.25 x | -14.6 x | 24.3 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.55 x | 1.52 x | 0.62 x | 0.16 x | 0.64 x | 0.48 x | 0.42 x |
| EV / Revenue | 2.55 x | 1.52 x | 0.62 x | 0.16 x | 0.64 x | 0.48 x | 0.42 x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 5,814 | 8,507 | 8,542 | 11,633 | 28,490 | 29,365 | - |
| Reference price 2 | 26.84 | 11.11 | 4.510 | 1.015 | 1.890 | 1.455 | 1.455 |
| Announcement Date | 3/12/20 | 3/31/21 | 4/8/22 | 3/30/23 | 3/21/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 61.3 | 62.2 | 61.93 | 72.81 | 83.61 | 88.97 | 101 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -34.53 | -28.42 | -30.34 | -16.78 | -6.67 | -1.95 | 2.864 |
| Operating Margin | -56.32% | -45.69% | -48.98% | -23.05% | -7.98% | -2.19% | 2.84% |
| Earnings before Tax (EBT) 1 | -34.13 | -30.89 | -32.67 | -18.68 | -8.439 | -3.15 | 2.053 |
| Net income 1 | -34.13 | -30.89 | -32.67 | -18.68 | -8.439 | -2.9 | 1.984 |
| Net margin | -55.67% | -49.66% | -52.76% | -25.65% | -10.09% | -3.26% | 1.96% |
| EPS 2 | -6.160 | -4.510 | -3.850 | -1.890 | -0.3600 | -0.1000 | 0.0600 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/31/21 | 4/8/22 | 3/30/23 | 3/21/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 15.99 | 15.33 | 18.68 | 18.69 | 19.31 | 19.67 | 18.08 | 23.77 | 22.09 | 21.7 | 21.8 | 22.18 | 23.29 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.972 | -8.359 | -4.482 | -3.708 | -1.966 | -1.427 | -2.959 | -1.737 | -0.547 | -0.8735 | -0.5795 | -0.3835 | -0.1135 |
| Operating Margin | -43.61% | -54.52% | -23.99% | -19.84% | -10.18% | -7.26% | -16.37% | -7.31% | -2.48% | -4.02% | -2.66% | -1.73% | -0.49% |
| Earnings before Tax (EBT) 1 | -7.581 | -8.941 | -4.967 | -4.19 | -2.362 | -1.75 | -3.305 | -1.872 | -1.512 | -1.328 | -0.864 | -0.655 | -0.302 |
| Net income 1 | -7.581 | -8.941 | -4.967 | -4.19 | -2.362 | -1.75 | -3.305 | -1.872 | -1.512 | -1.118 | -0.817 | -0.6185 | -0.346 |
| Net margin | -47.42% | -58.32% | -26.59% | -22.42% | -12.23% | -8.9% | -18.28% | -7.88% | -6.84% | -5.15% | -3.75% | -2.79% | -1.49% |
| EPS 2 | -0.8800 | -0.9900 | -0.5600 | -0.4000 | -0.1400 | -0.1000 | -0.1800 | -0.0700 | -0.0500 | -0.0400 | -0.0300 | -0.0200 | -0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 4/8/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/15/23 | 8/14/23 | 11/14/23 | 3/21/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 0.59 | 1.05 | - | 0.28 | 0.28 | - | - |
| Capex / Sales | 0.96% | 1.68% | - | 0.39% | 0.34% | - | - |
| Announcement Date | 3/12/20 | 3/31/21 | 4/8/22 | 3/30/23 | 3/21/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.455
USD
Average target price
7
USD
Spread / Average Target
+381.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.02% | 42.73M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- RMTI Stock
- Financials Rockwell Medical, Inc.
